期刊文献+

维生素D对前列腺增生小鼠血清生化指标的影响研究 被引量:3

Influence of vitamin D on the serum biochemical data of benign prostate hyperplasia mice
暂未订购
导出
摘要 目的通过观察维生素D对前列腺增生小鼠动物模型血清生化指标的影响,探讨不同剂量维生素D对前列腺增生动物模型的血清生化指标影响。方法应用丙酸睾酮肌肉注射制造小鼠前列腺增生模型。随机分组,采用不同剂量的维生素D剂喂养4周后,检测小鼠血清电解质、肝肾功能、血脂等指标。结果应用0.2、1.0和5.0μg/kg·d^(-1)的各组小鼠检测结果显示:应用维生素D对前列腺增生小鼠的肾功能无明显负面影响;但是大剂量维生素D对血清谷草转氨酶(AST)有升高作用;中、大剂量维生素D可以升高血清钙离子浓度,对镁、磷无明显影响。结论中、小剂量维生素D对小鼠前列腺增生模型的肝肾功能、电解质未发现明显负面影响,大剂量维生素D可能对血清钙离子浓度、AST有一定影响。 Objective To investigate the safety of vitamin D on mouse model with benign prostate hyperplasia by analyzing the changes of serum biochemical indexes in benign prostate hyperplasia mice. Methods Mouse model with BPH was established by injecting testosterone. All test mice were randomly divided into different groups. Mice in different groups respectively received different oral doses of vitamin D with 0, 0.2, 1.0, and 5.0ug/kg,d for four weeks. Levels of serum electrolyte, triglyceride, cholesterol, hepatic function, renal function were detected. Results Levels of serum ALT, AST, BUN, Cr, TG, TC, P, Mg, Ca in mice treated with 0, 0.2, 1.0 and 5.0 lag/kg of vitamin D were as follows: 55.2±9.6, 54.9±10.1, 55.1±11.9, 51.3±5.9; 188.3±24.7, 195.5±31.8, 204.9±51.0, 232.3±25.9; 10.6±1.2, 10.4±1.5, 8.9±1.1, 9.3±1.6;11.3±1.4, 11.3±2.9, 8.5±5.3, 9.8±1.6; 1.28±0.38, 1.14±0.25, 1.08±0.22, 1.00±0.31; 2.46±0.29, 2.45±0.35, 2.76±.68, 2.33±0.35; 1.67±0.19, 1.69±0.15, 1.64±0.17, 1.66±0.16; 1.66±0.07, 1.75±0.19, 1.70±0.14, 1.68±0.17; and 3.25±0.25, 3.33±0.28, 3.59±0.22, 3.65±0.17. The level of serum AST and the concentration of Ca were upregulated BY high dose of vitamin D (P〈0.01), whereas Changes of serum Mg and P werenot found Conclusion No injury was found in liver and kidney function of mice with BPH treated with small doses of vitamin D. But the liver function of mice with BPH might be affected by high dose of vitamin D.
出处 《中国男科学杂志》 CAS CSCD 2010年第2期9-11,共3页 Chinese Journal of Andrology
关键词 前列腺增生 维生素D 血清 生物化学 小鼠 prostatic hyperplasia vitamin D serum biochemistry mice
  • 相关文献

参考文献7

  • 1Chan JS, Beer TM, Quinn DI, et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 2008;102(11): 1601-1606.
  • 2Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008; 9(4): 272-278.
  • 3Tiwari A. Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007; 16(9): 1425-1439.
  • 4Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. lnt J Oncol 1998; 13(1): 137-143.
  • 5Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. Drugs 2009; 12(6): 381-393.
  • 6Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 2006; 49(1): 82-86.
  • 7Crescioli C, Morelli A, Adorini L, et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005; 90(2): 962-972.

同被引文献16

  • 1吴建辉,裴晓丹,曹霖,孙祖越,何桂林,刘桂明,蒋秀蓉.雌二醇对丙酸睾酮诱导去势大鼠前列腺增生的影响[J].中国药理学与毒理学杂志,2005,19(5):363-367. 被引量:11
  • 2Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol, 2014, 140: 116-132.
  • 3Barreto AM, Schwartz GG, Woodruff R, et al. 25- Hydroxyvitamin D3, the prohormone of 1, 25-di- hydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev, 2000, 9: 265-270.
  • 4Bae M, Woo M, Kusuma IW, et al. Inhibitory effects of isoflavonoids on rat prostate testosterone 5o-reductase. J Acupunct Meridian Stud, 2012, 5: 319-322.
  • 5Hong S J, Kim SI, Kwon SM, et al. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hy- perplasia. Yonsei Med J, 2002, 43 : 236-241.
  • 6Brssner C, Petritsch K, Fink K, et al. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urol- ogy, 2004, 64: 707-711.
  • 7Guy L, V6drine N, Urpi-Sarda M, et al. Orally adminis- tered isoflavones are present as glucuronides in the human prostate. Nutr Cancer, 2008, 60: 461-468.
  • 8Banerjee S, Li Y, Wang Z, et al. Multi-targeted therapy of cancer by genistein. Cancer Lett, 2008, 269: 226- 242.
  • 9Xiang-yun LIU,Dong-mei Li,Xiao-fang ZHANG,Jian-hui WU,Zu-yue SUN.Mitosis orientation in prostate epithelial cells changed by endocrine effect[J].Acta Pharmacologica Sinica,2008,29(2):226-229. 被引量:1
  • 10薛乐勋,王建民,葛秀峰,袁宝梅,许培荣.钙和维生素D抑制高脂饮食诱发的前列腺上皮细胞增生[J].现代预防医学,1999,26(3):331-333. 被引量:1

引证文献3

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部